[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinoblastoma-extraocular\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinoblastoma-extraocular":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100571816","detailed-phenotypic-and-genotype-study-to-correlate-rb1-mutations-relating-to-primary-ocular-tumors-and-secondary-extra-ocular-metastasis-100571816",false,"NCT06725173","Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.","Genetic Associations of Ocular Cancers","Inclusion Criteria:\n\n* Patients with molecularly proven retinoblastoma due to RB1 or a typical clinical retinoblastoma phenotype with genetic screening pending.\n* Able to give consent\u002Fparent or guardian able to give consent.\n\nExclusion Criteria:\n\n* Patients unable or unwilling to undertake consent or clinical testing.\n* Patients unwilling to donate a saliva or blood sample in order to establish the genetic cause of their condition.",true,"ALL",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is undertake a detailed phenotypic and genotypic study of patients with ocular and secondary cancers due to mutations in the RB1 gene. Our research sequencing approach will allow advanced insight to for further detailed genotypic understanding of parent-of-origin for valuable insight into the genotype-phenotype relationship of this cancer syndrome.",[24,25,26,27,28],"Retinoblastoma Bilateral","Retinoblastoma Unilateral","Retinoblastoma, Extraocular","Retinoblastoma, Recurrent","Retinoblastoma",[30,31],"retinoblastoma","parent-of-origin","RECRUITING","2026-03-17",{"date":35,"type":36},"2026-03-18","ACTUAL",{"date":38,"type":20},"2026-03-16",{"date":40,"type":20},"2031-01-01",{"name":42,"class":43},"University of Washington","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100431866","intrathecal-chemotherapy-for-central-nervous-system-metastasis-in-retinoblastoma-100431866","NCT04903678","Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma","Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma (A Multicenter Prospective Single Arm Trial)","Inclusion Criteria:\n\n* The pathological diagnosis was retinoblastoma. According to the IRSs (International retinoblastoma staging system) staging system, the stage was IVB\n* CSF tumor cells on cytology, or radiographic evidence of NM on MRI scans and histologic diagnosis of systemic malignancy needed\n* KPS≥60%\n* Adequate bone marrow and organ function\n* The parents signed the informed consent and were willing to accept the treatment and follow-up.\n\nExclusion Criteria:\n\n* 1.Eye diseases other than retinoblastoma\n* The eyes were infected within 30 days before screening\n* There was a history of surgery and \u002F or unhealed wound within 1 month before enrollment .\n* Those who have allergic reaction or allergic history to chemotherapeutic drugs.\n* Infectious diseases requiring oral, intramuscular or intravenous administration.\n* Patients with systemic immune diseases.\n* Active disseminated intravascular coagulation.\n* Abnormal coagulation function.\n* Abnormal bone marrow and organ function.\n* Uncontrollable clinical problems.\n* The researchers believe that those who need to be excluded.",{"count":53,"type":20},18,"INTERVENTIONAL",[56],"NA","Retinoblastoma is the most common intraocular malignancy in infancy and childhood. The overall survival rate of retinoblastoma was reported to exceed 95% when children were early diagnosed with localized intraocular phase. The advanced retinoblastoma cases with central nervous system metastasis (CNS)is associated with exceedingly poor prognosis. CNS metastasis is the main cause of death in retinoblastoma. Meningeal involvement combined with spinal cord membrane involvement might be due to the meninges invasion and\u002For the spreading of CSF.\n\nAs the most sensitive drug to retinoblastoma tumor cells in vitro, melphalan is the most important drug in the local treatment of retinoblastoma, and it is also an irreplaceable drug in the current eye preservation treatment, which greatly improves the success rate of eye preservation for advanced retinoblastoma. According to the research and the practice of vitreous injection (melphalan), the drug concentration in vitreous can effectively kill retinoblastoma tumor cells.\n\nIt is reasonable to speculate that the tumor cells in CSF can be effectively killed by melphalan. Therefore, based on the above background, this study will explore the effectiveness and feasibility of intrathecal injection of melphalan in patients with CNS metastasis of retinoblastoma through a multicenter prospective study.",[26],[30,60,61],"central metastases","intrathecal Chemotherapy","2025-02-24",{"date":64,"type":36},"2025-02-25",{"date":66,"type":36},"2021-05-01",{"date":68,"type":20},"2030-05-01",{"name":70,"class":43},"Eye & ENT Hospital of Fudan University"]